drugset / Trial / NCT04097925
Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals
Phase 2
Completed
30 enrolled
Fight AIDS and Infectious Diseases Foundation
Hospital Universitari de Bellvitge · collabInstitut d'Investigació Biomèdica de Bellvitge · collab
NaSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate the ability of Doravirine to penetrate the genital tract and suppress viral replication and provide evidence for the use of Doravirine as part of treatment strategies as prevention.
Timeline
- Start
- 2020-02-18
- Primary completion
- 2020-08-24
- Completion
- 2020-08-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doravirine | Small molecule | 100 mg | Oral |
| Background | emtricitabine | Other / unclassified | 200 mg | Oral |
| Background | tenofovir alafenamide | Small molecule | 25 mg | Oral |